PTC Therapeutics (PTCT) Misses Q2 EPS by 76c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/20/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
PTC Therapeutics Provides a Corporate Update and Reports Second Quarter Financial Results
August 4, 2022 4:01 PM EDTÂ - Total revenue of $166 million, representing 42% year-over-year growth Â
- Upstaza gene therapy granted marketing authorization by European Commission for treatment of AADC deficiency with first commercial patient treated
SOUTH PLAINFIELD, N.J., Aug. 4, 2022 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced a corporate update and financial results for the second quarter ending June 30, 2022.Â
"We made significant progress in the second quarter toward achieving our ambitious goals for 2022. We continued to... More
